193 related articles for article (PubMed ID: 12743148)
21. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis.
Yabe H; Tsukahara T; Kawaguchi S; Wada T; Sato N; Morioka H; Yabe H
Oncol Rep; 2008 Jan; 19(1):129-34. PubMed ID: 18097586
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
[TBL] [Abstract][Full Text] [Related]
25. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
[TBL] [Abstract][Full Text] [Related]
26. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
Scotlandi K; Benini S; Sarti M; Serra M; Lollini PL; Maurici D; Picci P; Manara MC; Baldini N
Cancer Res; 1996 Oct; 56(20):4570-4. PubMed ID: 8840962
[TBL] [Abstract][Full Text] [Related]
27. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
28. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
[TBL] [Abstract][Full Text] [Related]
29. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
Yoshitani K; Honoki K; Morishita T; Kido A; Miyauchi Y; Mii Y; Takakura Y
In Vivo; 2003; 17(3):255-8. PubMed ID: 12929576
[TBL] [Abstract][Full Text] [Related]
30. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
[TBL] [Abstract][Full Text] [Related]
31. Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics.
Kikuta K; Tochigi N; Shimoda T; Yabe H; Morioka H; Toyama Y; Hosono A; Beppu Y; Kawai A; Hirohashi S; Kondo T
Clin Cancer Res; 2009 Apr; 15(8):2885-94. PubMed ID: 19351769
[TBL] [Abstract][Full Text] [Related]
32. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
[TBL] [Abstract][Full Text] [Related]
33. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.
Beghini A; Bellini M; Magnani I; Colapietro P; Cairoli R; Morra E; Larizza L
Exp Hematol; 2005 Jun; 33(6):682-8. PubMed ID: 15911092
[TBL] [Abstract][Full Text] [Related]
34. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
35. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
36. Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness.
Meynet O; Scotlandi K; Pradelli E; Manara MC; Colombo MP; Schmid-Antomarchi H; Picci P; Bernard A; Bernard G
Cancer Res; 2010 May; 70(9):3730-8. PubMed ID: 20388798
[TBL] [Abstract][Full Text] [Related]
37. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
38. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
[TBL] [Abstract][Full Text] [Related]
39. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type.
Benini S; Perbal B; Zambelli D; Colombo MP; Manara MC; Serra M; Parenza M; Martinez V; Picci P; Scotlandi K
Oncogene; 2005 Jun; 24(27):4349-61. PubMed ID: 15824736
[TBL] [Abstract][Full Text] [Related]
40. KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes.
Bellone G; Smirne C; Carbone A; Buffolino A; Scirelli T; Prati A; Solerio D; Pirisi M; Valente G; Nano M; Emanuelli G
Int J Oncol; 2006 Oct; 29(4):851-9. PubMed ID: 16964380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
